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ABSTRACT
In the fight against antimicrobial resistance, the bac-
terial DNA sliding clamp, -clamp, is a promising
drug target for inhibition of DNA replication and
translesion synthesis. The -clamp and its eukary-
otic homolog, PCNA, share a C-terminal hydrophobic
pocket where all the DNA polymerases bind. Here we
report that cell penetrating peptides containing the
PCNA-interacting motif APIM (APIM-peptides) inhibit
bacterial growth at low concentrations in vitro, and
in vivo in a bacterial skin infection model in mice.
Surface plasmon resonance analysis and computer
modeling suggest that APIM bind to the hydropho-
bic pocket on the -clamp, and accordingly, we
find that APIM-peptides inhibit bacterial DNA repli-
cation. Interestingly, at sub-lethal concentrations,
APIM-peptides have anti-mutagenic activities, and
this activity is increased after SOS induction. Our
results show that although the sequence homology
between the -clamp and PCNA are modest, the
presence of similar polymerase binding pockets in
the DNA clamps allows for binding of the eukary-
otic binding motif APIM to the bacterial -clamp. Im-
portantly, because APIM-peptides display both anti-
mutagenic and growth inhibitory properties, they
may have clinical potential both in combination with
other antibiotics and as single agents.
INTRODUCTION
The DNA sliding clamps are functionally and structurally
conserved in all three domains of life, although the sequence
homologies are modest (1). Two interacting motifs are iden-
tified for the trimeric eukaryote DNA sliding clamp PCNA;
the PCNA interacting peptide (PIP)-box (Q-xx--xx-)
( = aromatic,  = hydrophobic, x = any residue) (2)
and the AlkB homolog 2 PCNA Interacting Motif (APIM)
(R/K- F/W/Y- L/I/V/A- L/I/V/A- K/R) (3). Whereas
the PIP-box is found in many proteins essential for DNA
replication, APIM is more frequently found in proteins im-
portant for handling of cellular stress, including proteins in-
volved in DNA repair and translesion synthesis (TLS) (3–
9). APIMand PIP-box have overlapping interaction sites on
PCNA that both include the conserved hydrophobic pocket
below the interdomain connecting loop (IDCL) (10,11).
PCNA is a homotrimer, while the prokaryotic DNA slid-
ing clamp, the -clamp, is a homodimer and a subunit of
the DNA polymerase III (Pol III) holoenzyme (12). The
-clamp is highly conserved between bacteria (13), and a
loosely defined -clamp binding motif of 5–6 amino acids
(QL-x1–2-LF) (CBM), found in all prokaryotic DNA poly-
merases (14,15), is suggested to be the prokaryotic ancestor
to the PIP-box. CBM interacts with the hydrophobic pocket
at the C-terminal part of the -clamp (16,17), similar to the
APIM and PIP-box interactions with PCNA.
More than 600 mammalian proteins contain either
APIM or the PIP-box, and can thus potentially interact
with PCNA via a common interaction region (18). Bind-
ing to PCNA is therefore highly regulated by multi-layered
mechanisms, which includes different post-translational
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modifications (PTMs) and large variations in binding affini-
ties within and between the two interactionmotifs (reviewed
in (19,20)). For example, APIM-EYFP overexpression does
not affect cell proliferation under unperturbed conditions,
while PIP-box-EYFP overexpression in human and yeast
cells is cytotoxic, likely due to inhibition of replication
(3,21). APIM-EYFP overexpression, on the other hand,
does not impair DNA replication but induces hypersensitiv-
ity toward chemotherapeutics, and APIM-EYFP is shown
to pull down PTM variants of PCNA (3). PCNA modifi-
cations after cellular stress increase the affinity for APIM,
e.g. poly-ubiquitination (22), and it is therefore suggested
that mainly cellular stress defense mechanisms are impaired
by APIM-peptides (10,23–26). It is not known if interac-
tions between the -clamp and different groups of protein-
containing CBMs are similarly regulated.
The high-fidelity replicative polymerase III (Pol III) can-
not replicate through bulky lesions in DNA. To prevent
replication fork collapse and DNA double-strand breaks
upon stalling of replication forks, cells utilize DNA dam-
age tolerance mechanisms to bypass fork-stalling lesions.
This lesion bypass occurs mainly after the re-initiation of
new replications forks in a process where the replication
fork skips the lesion and re-primes downstream of the le-
sion. The gaps left behind are filled using either the ho-
molog DNA strand as a template or by utilizing specialized
TLS polymerases which can polymerize over the lesions (re-
viewed in (27)). Because bypass by TLS polymerases often
is done in an error-prone manner, these polymerases are im-
portant contributors to point mutations and thus essential
in the development of drug resistance in both prokaryotes
and eukaryotes (28–30). The catalytic subunit REV3L of
the human polymerase POL  and the RAD5 homologs
HLTF and SHPRH, all involved in TLS, were recently
shown to have functional APIM PCNA interacting mo-
tifs, and targeting PCNA with APIM-peptides were shown
to reduce the mutation frequency after UV-induced DNA
damage in several cell lines (8,9). Direct interactions be-
tween the -clamp and the prokaryotic TLS polymerases
Pol II, Pol IV and Pol V, are shown to be vital for their TLS
activity (31).
Pol II and Pol IV are expressed at low levels also in
the absence of stress (30–50 and ∼250 copies per cell, re-
spectively), but during SOS their expression is increased
7- to 10-fold. Pol V (UmuD’2C) on the other hand is al-
most completely SOS controlled, and functional Pol V is
mainly detected after SOS-induction (32). It is believed that
the concentration of the TLS polymerases, which are con-
trolled by SOS, is the main trigger for TLS (reviewed in
(27), but that low levels of constitutively expressed Pol II
and Pol IV participate at stalled replication forks in ab-
sence of full SOS (33). The expression of mammalian TLS
polymerases is more constant and not rapidly induced upon
stress; however, their activities are tightly regulated to avoid
excessive mutations. This includes regulation of their affin-
ity for the DNA clamp, e.g. PCNA is mono-ubiquitinated
upon stalling of replication and mono-ubiquitination is be-
lieved to be important in the regulation of the polymerase
switch from the replicative polymerases to TLS polymerases
in eukaryotic cells (reviewed in (34)). It is not shown that
prokaryotes utilize the ubiquitin system for maintaining
balanced systemic responses, but it is shown that they have
several ubiquitin ligase enzymes that can hijack the ubiq-
uitin system of various hosts (35). Prokaryotes also con-
tain several ubiquitin-like peptide systems (36–38). How-
ever, whether PTMs, ubiquitin-like or others, are added to
the -clamp after stalling of the replications fork, and ex-
actly how the switch from replicative polymerases to TLS
polymerases is regulated in prokaryotes is elusive.
APIM-peptides interact with PCNAand are shown to af-
fect DNA repair, TLS, apoptosis and cell signaling in mam-
malian cells, and to have anti-cancer efficacy inmultiple pre-
clinical animal models (4,8–10,18,23–26,39). A lead APIM-
peptide, ATX-101, is currently in an ongoing Phase I clini-
cal safety (maximal tolerated dose)-trial in cancer patients,
initiated fall of 2018. Here, we show that APIM-peptides
also have antibacterial activities both in vitro and in vivo.
The APIM-peptides inhibit replication via interaction with
the -clamp, a promising drug target (40,41) (reviewed in
(13,42)). Reduced mutation frequency after the addition
of sub-lethal concentrations of the APIM-peptides indi-
cates that the interactions between TLS polymerases and
the -clamp are inhibited by APIM-containing peptides at
lower concentrations than the replicative polymerase. Be-
causemutations introduced by TLS polymerases are impor-
tant in the development of antimicrobial resistance (AMR),
the anti-mutagenic activity of the APIM-peptides could
have a large potential for use in combination with other an-
tibiotics to prevent the development of resistance. In addi-
tion, the APIM-peptides efficiently inhibit bacterial growth
at low concentrations inmultidrug-resistant Staphylococcus
epidermidis and Staphylococcus aureus.
MATERIALS AND METHODS
Species, strains, materials, growth measurements
S. aureus: ATCC 29213, FDA486, methicillin-resistant
S. aureus strain (MRSA) 43484 and FusA88779; S. epi-
dermidis: clinical isolates (including one gentamicin sen-
sitive strain and several multidrug-resistant strains) from
Department of Microbiology, St. Olavs University Hospi-
tal, Trondheim, Norway, kindly provided by professor Ka˚re
Bergh; Escherichia coli: strains DH5, BL21 (RIPL) DE3
(Novagen), K12 (MG1655) wild type (WT) and TLS dele-
tion strains (Pol II3, Pol IV1, Pol V1, Pol II/IV3,
Pol II/V3, Pol IV/V2 and Pol II/IV/V3). 1 Keio col-
lection, 2 generated by Prof Magnar Bjøra˚s’ group, UiO
and 3prepared as described (43). Briefly, polB was inacti-
vated in E. coli MG1655 WT, Pol IV, Pol V and Pol
IV/V using JW0059:: polB. A phage stock (T4GT7) diluted
in T4 buffer was added to the JW0059::polB culture, incu-
bated and plated on LB agar plates. The lysate was har-
vested and added to 2 ml T4 buffer and 0.2 ml CHCl3
(T4GT7 lysate). The mixture was centrifuged, and super-
natant stored at 4◦C over 20 l CHCl3. 0.5 ml overnight
culture of the recipient cells was re-suspended in 1 ml of
T4 buffer and aliquoted. The T4GT7 lysate (10−1, 10−2,
10−3 and 10−4 dilutions) was added to the aliquots, incu-
bated for 25 minutes (min) at room temperature and plated
on LB-agar plates with kanamycin. Colonies obtained were
re-streaked twice to obtain a pure culture. Kanamycin re-
sistance cassettes replacing the deleted polB genes were re-
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Table 1. Peptides used in the different experiments
Cell penetrating
peptides Sequence Used in experiments
RWLVK Ac-MD-RWLVK-WKKKRKI-RRRRRRRRRRR MIC-assay, RifR assay, MST
RWLVK* Ac-MD-RWLVK-GILQWRKI-RRRRRRRRRRR MIC-assay, DNA replication assay, RifR assay
RFSLK Ac-MD-RFSLK-WKKKRKI-RRRRRRRRRRR MIC-assay, Mutation frequency (GenR) assay,
RifR assay, In vivo skin model, MST
RFSLK* Ac-MD-RFSLK-GILQWRKI-RRRRRRRRRRR MIC-assay
RALVK Ac-MD-RALVK-WKKKRKI-RRRRRRRRRRR MIC-assay, RifR assay, MST
RWLK Ac-MD-RWLK-WKKKRKI-RRRRRRRRRRR MIC-assay, RifR assay, MST
R11 RRRRRRRRRRR MIC-assay, DNA replication assay, RifR assay,
MST
Overexpressedpeptides
RWLVK MD-RWLVK- GILQSTLA RifR assay, Overexpression (viability) assay
RFSLK MD-RFSLK- GILQSTLA RifR assay, Overexpression (viability) assay
RALVK MD-RALVK- GILQSTLA Overexpression (viability) assay
RWLK MD-RWLK- GILQSTLA RifR assay, Overexpression (viability) assay
Octamerpeptides
RWLVK Ac-MDRWLVKW SPR analysis, NMR spectroscopy
RALVK Ac-MDAWLVKW SPR analysis, NMR spectroscopy
Pol III peptide Ac-EQVELEFD NMR spectroscopy
*= different linker between APIMmotif and cell penetrating part (R11). The C-termini on all peptides were amidated. All peptides were TFA-salt (>90%
pure). Lyophilized peptide from the manufacturer was dissolved in stock solutions of 1 mM peptide in water.
moved by an FLP-recombinase expressed by pCP20 plas-
mid.
Verification of the deletions strains was done by poly-
merase chain reaction (PCR) using the following primers:
 Pol II strain: 5′-GATTCCAGCAACCGGCACCAC-
3′ and 5′-CAGGCGAGTACCGATATAGG-3′
 Pol IV strain: 5′-TATGTTTGAACGCGGCAGCG-3′
and 5′-AGTCATTGAAATCATCATCC-3′
 Pol V strain: 5′-TGTTTAATGTCATTATGGCG-3′
and 5′-AAGTGTTTGTCGCCTCTGGC-3′
Minimal inhibitory concentration assay
Minimal inhibitory concentration (MIC) was determined
following the protocol recommended by the National Com-
mittee of Laboratory Safety and Standards (NCCLS, (44))
for microtiter broth dilution assay, conducted with modifi-
cations suggested by R.E.W. Hancock Lab for cationic pep-
tides (45). Briefly, bacterial suspension in Mueller-Hinton
Broth was adjusted to 0.5McFarland and diluted to 5× 105
CFU/ml. The suspension (0.1 ml) was seeded in polypropy-
lene microtiter plates (Greiner), 5 × 104 CFU/well. APIM-
peptides were added as 10% of the total volume. Initial in-
oculums were quantified by seeding on agar for verification
of the estimated CFU/mL. After 24 hours (h) incubation at
37◦C, themicrotiter plates were inspected for visible growth.
Determination of minimal inhibitory concentrations
(MICs) for S. aureus was done at Statens Serum Institute,
Copenhagen, Denmark.
Cultivation
Growth experiments were performed in Luria-Bertani
broth (LB) media, Tryptic soy broth (TSB) or LB agar at
37◦C, antibiotic selections were performed using the follow-
ing concentrations: kanamycin 30 g/ml, chloramphenicol
34 g/ml and rifampicin 100 g/ml.
Peptides
Table 1 shows an overview of the peptides (Innovagen, Swe-
den) used.
Cloning and overexpression
Oligonucleotides (Sigma) for annealing and cloning of
APIMs into the NcoI/NheI site of pET28a(+) (Novagen):
RWLVK: 5′-CATGGACAGATGGCTGGTGAAAGGAATT
CTGCAGTCGACG-3′ and
5′-CTAGCGTCGACTGCAGAATTCCTTTCAC
CAGCCATCTGTCC-3′,
RFSLK: 5′-CATGGACAGATTTAGTCTGAAAGGAATT
CTGCAGTCGACG-3′ and
5′-CTAGCGTCGACTGCAGAATTCCTTTCAG
ACTAAATCTGTCC-3′,
RFLSK: 5′-CATGGACAGATTTCTGAGTAAAGGAATT
CTGCAGTCGACG-3′ and
5′-CTAGCGTCGACTGCAGAATTCCTTTACT
CAGAAATCTGTCC-3′,
RALVK: 5′-CATGGACAGAGCTCTGGTGAAAGGAATT
CTGCAGTCGACG-3′ and
5′-CTAGCGTCGACTGCAGAATTCCTTTCAC
CAGAGCTCTGTCC-3′,
RWLK: 5′-CATGGACAGATGGCTGAAAGGAATTCTG
CAGTCGACG-3′ and
5′-CTAGCGTCGACTGCAGAATTCCTTTCAG
CCATCTGTCC-3′.
A stop codon is found in the multiple cloning site after
the NcoI/NheI site. The sequence over-expressed is MD-
APIM-GILQSTLA.
APIM-EYFP constructs
APIM-sequences (RWLVK and RWLK) were fused with
EYFP in the pEYFP vector (Clonetech) and were cloned
into pET28a(+) using the NcoI/NheI sites. Peptide vari-
ants (RFSLK and RALVK) were made by site-directed
mutagenesis by GenScript. All constructs were confirmed
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by sequencing performed by GATC Biotech. Cloning was
performed in E. coli DH5. Expression levels of APIM-
EYFP were measured by western analysis. Briefly, cell pel-
lets were boiled in OmniCleave™ buffer, followed by in-
cubation with OmniCleave™ endonuclease (200 U). Sam-
ples were next added lithium dodecyl sulphate (LDS) load-
ing buffer (Invitrogen, ThermoFisher Scientific) containing
100 mM DTT and incubated 10 min at 70◦C before loaded
on a 4–12% polyacrylamide gel (NuPAGE™, Invitrogen).
Proteins were blotted to a PVDF membrane (Immobilon,
0.2 M), blocked in 5% bovine serum albumin. Antibodies
utilized were GFP (Ab290, Abcam) and IRDye® 680RD
goat -rabbit (LI-COR).
Overexpression experiments in E. coli BL21
Induction was performed using isopropyl -D-1-
thiogalactopyranoside (IPTG) (1 mM) at OD600 = 0.3
- 0.4. Bacterial growth was measured by OD600 or the
number of colony-forming units (CFU) per ml.
Replication assay
E. coli MG1655 cells were grown at 37◦C in glucose-CAA
medium (AB minimal medium (46) supplemented with 10
g/ml thiamine, 0.2% glucose and 0.5% casamino acids) for
several generations to ensure balanced growth. At anOD600
= 0.15, the cells were added 2, 4 or 6 MRWLVK* peptide
or 2, 4, 6 or 15 M R11 peptide. Growth was continued
for 2–5 min. After peptide treatment, cells were either har-
vested directly or treated with rifampicin (Rif) (300 g/ml)
and cephalexin (Cpx) (10 g/ml) for the time equivalent of
three to four generations before harvesting. Both directly
harvested and Rif and Cpx treated cells were re-suspended
in TE buffer (10 mM Tris–HCl, pH 8.0, 1 mM EDTA, pH
8.0) and fixed in 70% ethanol. Fluorescein isothiocyanate
(FITC, Sigma-Aldrich) (47) was used for protein staining
(representing mass), and Hoechst 33258 was used for DNA
staining (Sigma-Aldrich) (48). Flow cytometry was per-
formed with an LSR-II flow cytometer equipped with a 488
nm argon-ion laser and a 355 nm krypton laser (BD Bio-
sciences), and the results were analyzed using FlowJo soft-
ware (Tree Star, Inc.). Rif and Cpx inhibit the initiation of
replication and cell division, respectively. Cells cannot initi-
ate a new round of replication after these drugs are added
but can complete ongoing rounds of replication (without
dividing). Therefore, DNA histograms of the Rif and Cpx
treated cells give an integer number of chromosomes per cell
with values 2n or 2n+1, where n = 0, 1, 2, 3. . . represents the
generation in which initiation occurs. However, this pattern
holds true only for cells with successful completion of repli-
cation elongation (all initiated replication forks reaching the
terminus). Problemswith replication elongation will be seen
as a lack of distinct peaks in the ‘run-out’ DNA histograms
(i.e. histograms of cells treated with Rif and Cpx).
Site-directed mutagenesis of the -clamp
The plasmid containing the dnaN gene encoding -
clamp, pET-16b, was isolated from E. coli BL21. Site-
directed mutagenesis was performed following the Strata-
gene QuikChange® Site-Directed Mutagenesis Kit proto-
col (Revision A, 2006). The single residues were mutated
using the following oligonucleotides (Sigma):
H148K 5′-CAGTTTTCTATGGCGAAACAGGACGTTCGC
TATTAC-3′
5′-GTAATAGCGAACGTCCTGTTTCGCCATAGA
AAACTG-3′
V151A 5′-GGCGCATCAGGACGCTCGCTATTACTTAAA
TGG-3′
5′-CCATTTAAGTAATAGCGAGCGTCCTGATGC
GCC-3′
P242D 5′-GGTCGCTTCGACGATTATCGCCGCGTTC-3′
5′-GAACGCGGCGATAATCGTCGAAGCGACC-3′
V247F 5′-
GGATTATCGCCGCTTTCTGCCGAAGAACCC-3′
5′-
GGGTTCTTCGGCAGAAAGCGGCGATAATCC-
3′
M362D 5′-GCGGCTTATGTTGTCGATCCAATGAGACTG-
3′
5′-
CAGTCTCATTGGATCGACAACATAAGCCGC-3′
P363D 5′-
GCGGCTTATGTTGTCATGGACATGAGACTG-3′
5′-CAGTCTCATGTCCATGACAACATAAGCCGC-
3′
Purification of -clamp protein
E. coli BL21 cultures were grown and induced for protein
expression of His-tagged WT and mutant -clamp from
pET-16b (including dnaN gene) with 300 M IPTG at
OD600 = 0.1–0.2.The bacterial cultureswere centrifuged 2 h
after induction with IPTG and pellets were lysed with lysis
buffer containing 1 mg/ml lysozyme (Sigma-Aldrich) and
sonicated (Branson Sonifier 250). The His-tagged -clamp
was purified using a TALON® superflow™ metal affin-
ity resin (Clonetech Laboratories Inc.) and NaP-buffers
(50 mM, pH 8) supplemented with 300 mM NaCl, 0.01%
tween and 10 mM -mercaptoethanol, followed by imida-
zole elution (150 mM). To concentrate the proteins the elu-
tion buffer was run throughAmicon®Ultra centrifugal fil-
ters (Ultracel® 10K,MerckMillipore). The proteins in the
centrifuge filter were washed out with phosphate-buffered
saline (PBS) and finally added glycerol (50%) for storage.
For nuclear magnetic resonance (NMR) spectroscopy, the
pellet was resuspended in lysis buffer (20 mM Tris, 100 mM
NaCl, 2.5 mM MgCl2, 0.5 mM CaCl2, 10 g/l DNase
1, pH 7.4) and lysed by French Press at 20 KPSI and
subsequently centrifuged at 20 000 g for 30 min at 4◦C.
The supernatant was loaded onto a 5 ml HisTrap FF pre-
equilibrated in binding buffer (20 mM Tris, 100 mM NaCl
pH 7.4) and afterward washed with five column volume
(CV) wash buffer (20 mM Tris, 100 mM NaCl, 10 mM Im-
idazole pH 7.4). The protein was eluted with 2 CV elution
buffer (20 mM Tris, 100 mM NaCl, 250 mM imidazole pH
7.4) and loaded onto a size exclusion chromatography col-
umn (HiLoad 16/600 Superdex 200 pg) for further purifi-
cation using 20 mM NaH2PO4, 100 mM NaCl, pH 7.4.
-clamp binding assays
Microscale thermophoresis (MST). Purified E.coli -
clamp (49) was labeled using theRED-Maleimide Labelling
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/48/10/5540/5826810 by R
oyal Library C
openhagen U
niversity user on 22 June 2020
5544 Nucleic Acids Research, 2020, Vol. 48, No. 10
Kit (NanoTemper Technologies, GmbH) according to the
manufacturer’s instructions applying a concentration of 20
Mprotein at room temperature. The ligands, cell penetrat-
ing APIM-peptides, were dissolved and diluted in supple-
mented Microscale thermophoresis (MST) buffer (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 10 mM MgCl2) with 2%
fetal bovine serum and incubated for 10 min in room tem-
perature. Series of 1:1 dilutions (16×), producing ligand
concentrations ranging from 500 M to 15 nM, were made.
Each ligand solution was further diluted 1:1 with fluores-
cent labeled -clamp (diluted in MST buffer, 3 nM) and
incubated for 10 min. Fluorescence was measured for each
protein-ligand sample using aMonolith NT.115 instrument
(20%MSTpower and 100%LEDpower) andMonolithNT
Standard TreatedCapillaries (bothNanoTemper Technolo-
gies, GmbH). To calculate the KD’s, fluorescence signals
were plotted and analyzed using the supplemented software
(NTAnalysis software version 1.5.41 andMO.affinity anal-
ysis version 2.2.4, NanoTemper Technologies). Denatura-
tion with SD-buffer (4% sodium dodecyl sulphate and 40
mM DTT) and re-measurement of total fluorescence con-
firmed that the observed change in fluorescence was due to
ligand binding event.
NMR spectroscopy. Each octamer peptide
(MDRWLVKW, MDRALVKW or Pol III -clamp
binding peptide EQVELEFD, APIM and potential CBM
underlined) was added sub-stoichiometric amounts of
-clamp depending on the expected affinities (100 or 50
M peptide added 5 or 20 M -clamp, respectively). All
NMR spectra were recorded in a standard 5 mm NMR
tube at 298 K in 20 mM NaH2PO4, 100 mM NaCl, pH
7.4, 0.25 mM DSS, 10% D2O on a Bruker AVANCE III
800-MHz (1H) spectrometer equipped with a room temper-
ature probe. Free induction decays were transformed and
analyzed in Topspin (Bruker Biospin) and the aromatic
region assigned.
Surface plasmon resonance (SPR) analysis. The experi-
ment was performed with Biacore S200 (GEHealthcare), at
25◦Cwith a flowrate of 30l/min. PurifiedWT andmutant
-clamp protein were immobilized by amine coupling on
CM5 Series S sensor chips (GE Healthcare). The proteins
were immobilized in 10 mM sodium acetate buffer with pH
4.0 until a level of approximately 2000 response units (RU)
were reached in flow channel number two or four, leaving
flow channel number one or three as reference channels.
Octamer peptides containing APIM motifs (underlined)
MDRWLVKWandMDRALVKWwere diluted in running
buffer (PBS P+ buffer: 20 mM phosphate buffer pH 7.4,
3 mM KCl, 137 mM NaCl, 0.05% surfactant P20) at 4, 8,
16, 32, 64 and 128 M, and analyzed by single-cycle mode.
Six consecutive injections of alternating running buffer or
peptide in running buffer, with an association phase of 120
seconds (s) followed by a dissociation phase of 60 s and
a final dissociation phase of 600 s, were run for each -
clamp protein variant. The running buffer series were used
as blanks together with the signal from the reference chan-
nels for double-reference subtraction. After each series of
six injections, the sensor chip was washed with a 120 s re-
generation injection of 1 M NaCl followed by a 120 s in-
jection of running buffer. The sensorgrams were processed
(reference subtracted) with Biacore S200 Evaluation Soft-
ware Version 1.1 (GE Healthcare) and normalized accord-
ing to the immobilized level. Data were exported to Origin
2017 (OriginLab) for the preparation of figures.
Mutagenesis assays. The rifampicin resistance (RifR) mu-
tagenicity assay was performed as described in (50) with
some modifications. Briefly, E. coli BL21 expressing pep-
tide variants were induced with (IPTG) (1 mM) at OD600 =
0.3–0.4 and cultured at 37◦C, for 2 h before harvested. Bac-
teria from large culture volumes (up to 50 ml) were plated
in order to obtain ∼100 RifR colonies per dish. The anti-
mutagenic effect of cell penetrating APIM-peptides in E.
coliMG1655 was done by adding 20 M peptide at OD600
= 0.01, and the cells were cultured for 30min.Next, the cells
were pelleted and washed with PBS before UV-irradiated in
(50 l) PBS (2 mJ UVC/cm2), re-suspended in 2.5 ml LB
and cultured in 37◦C for 2 h before plating onLBplates with
andwithoutRif (100g/ml). The number of RifR colonies/
total CFU was determined after 1 and 2 days, respectively.
Significance was calculated by using a two-tailed, paired,
students t-test.Gentamicin resistance (GenR)was examined
using a gentamicin sensitive clinical isolate ofS. epidermidis.
The overnight culture was diluted (1:100) into 4 ml TSB
with an addition of∼50%MIC of gentamicin (0.25g/ml),
APIM-peptide (3 M), a combination of these or a corre-
sponding amount of water as a control. The cultures were
grown in a shaking incubator (37◦C) andwere re-inoculated
(1:100) every 24 h in fresh TSB and supplements. The cul-
tures were plated on blood agar plates with and without
gentamicin (10mg/l) every day for 4 days, and the frequency
ofGenR colonies was determined by calculating the number
of GenR colonies/total CFU.
Structural modeling. Atomic coordinates of -clamp in
complex with a peptide from DNA polymerase V (PDB
code: 4k74, (17)) were retrieved and the residues QLNLF in
the Pol V peptide were replaced with the residues MDRWL
from theAPIMmotif, based on a sequence alignmentwhere
hydrophobic residues WL in the APIM motif are aligned
with the corresponding hydrophobic LF motif in Pol V
CBM. There are no residues in the template peptide to
model the last two residues (VK) in the APIM motif. With
this alignment, the key residue W in APIM can point into
the hydrophobic pocket formed by, among others, residues
V247 and M362 in the clamp. This initial model was used
as an input for the Rosetta FlexPepDock protocol for high-
resolution modeling of peptide-protein interactions (51) to
generate alternative models for the interaction.
Murine skin wound infection model. The experiment was
performed at Microbiology and Infection Control, Statens
Serum Institute, Copenhagen, Denmark, approved by the
National Committee of Animal Ethics, Denmark. The ex-
perimental procedure is modified from a previously de-
scribed skin infection model in mice (52). A total of 32
Balb/C female mice (18–22 g, Taconic, Denmark) were
used for the experiment. The mice were treated orally with
analgesia, 45 l Nurofen®junior (Novartis 20 mg/ml ∼30
mg/kg), 30–60 min before the experiment. The mice were
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anesthetized with 0.15 ml diluted Zoletil mix (2 ml Zoletil
mix + 5.2 ml sterile saline + 2.8 ml Torbugesix 1:100) before
the fur was removed on a 2 × 3 cm area of the back with an
electric shaver and a razor. At last, a skin lesion was made
on each mouse with a dermal curette (Miltex 335710). A
total of 10 l inoculum containing 107 CFUMRSA 43484
(in saline) was added to a 1 cm2 area of the skin lesion
of each mouse. One group of animals (six mice) were sac-
rificed 1 day after inoculation, before any treatment was
given, to quantify the inoculum. The remaining mice were
given topical treatment twice a day (9 a.m and 3 p.m) for 3
days; APIM-peptide (RFSLK, Innovagen SE, 12.8 mg/ml
in 1% methyl cellulose gel containing 10% glycerol) or Fu-
sidic acid 2% ointment (LeoPharma). A volume of 50 l
was used for each treatment, spread out on the skin lesion.
One group of mice did not get any treatment and repre-
sent the control group. The treated animals and the con-
trol group were sacrificed on day 4, one day after the last
treatment. The skin lesion area was removed by a pair of
tweezers and scissors and collected in 1 ml saline before be-
ing homogenized in a Dispomixer. Each sample was seri-
ally diluted in saline/Triton-X and 20 l spots were applied
on Mueller Hinton/PolymyxinB 3% NaCl plates and incu-
bated 24–48 h at 35◦C. The mice did not show any clinical
signs of systemic infection or distress.
RESULTS AND DISCUSSION
APIM-peptides have growth inhibitory activity in several bac-
terial species
During an accidental bacterial infection in our mammalian
cancer cell cultures, we observed that in wells where APIM-
peptide was added, the cell media looked normal, while
in parallel wells without APIM-peptide, the cultures were
overgrown with bacteria. At low APIM-peptide concen-
trations the cancer cells were growing normally; however,
no bacterial growth was seen, indicating that the APIM-
peptide had antibacterial activity at concentrations not in-
hibiting cancer cell proliferation (data not shown). It is well
known that cationic peptides may have broad-spectrum an-
timicrobial activities, and this includes both synthetic pep-
tides, such as cell penetrating peptides, and peptides syn-
thesized by bacteria or eukaryotes (53). Much of the an-
tibacterial effects of these cationic peptides are believed to
be caused by disruption of the bacterial cell membrane.
However, because PCNA and -clamp share structural fea-
tures, the antibacterial activity observed could possibly also
be mediated by the PCNA interacting motif, APIM, which
may interact with the-clamp and thereby prevent bacterial
replication.
To explore the antibacterial activity of peptides contain-
ing APIM further, activities of cell penetrating peptides
containing different APIM-consensuses were examined in
both Gram negative and positive bacterial species. Low
MICs were detected in both multidrug resistant S. epider-
midis and S. aureus strains and in the laboratory E. coli
strains BL21 and MG1655 with the RWLVK and RFSLK
peptide variants (Figure 1A and C). For two of the re-
sistant S. aureus strains, the RWLVK-peptide was much
more efficient than the corresponding molar concentration
of Ciprofloxacin (Figure 1A). The antibacterial activity var-
ied between different bacterial species, and between differ-
ent isolates of bacteria within the same species, as shown
for different clinical isolates of multidrug-resistant S. epi-
dermidis (Figure 1B).Why some clinical isolates ofS. epider-
midis are more sensitive to the APIM-peptide than others is
not known; however, it could be speculated that mutations
leading to loss of fitness are more pronounced in the most
sensitive isolates. Different sensitivity toAPIM-peptides be-
tween different bacterial species could also be due to differ-
ence in the bacteria’s ability to import and digest the pep-
tide (i.e. peptide stability), and/or differences between the
-clamps even though they have high structural homology
(54).Differences in sensitivity toward theAPIM-peptide are
also seen between different cancer cell lines (10,39). Because
cell penetrating peptides often have antibacterial activity on
their own, we included a peptide containing only the cell
penetrating part of the APIM-peptide, i.e. R11 (11 argi-
nine residues). We found no effect of this peptide on the
most sensitive of the clinical isolates of S. epidermidis at
the same molar concentration as the full-length cell pene-
trating RWLVK-peptide (Figure 1B, compare line marked
1 R11 with the line marked 1). Furthermore, when compar-
ing different APIM-peptide variants, MICs were lowest for
the variants named RFSLK* and RWLVK*, and highest
for the truncated APIM (RWLK) and the peptide contain-
ing only the cell penetrating part (R11) in bothE. coli andS.
epidermidis (Figure 1C). These results indicate that the full-
length peptides containing a 5-residueAPIMhave strongest
antibacterial activity. To examine if this additional growth
inhibition were due to interactions of APIM with an intra-
cellular target, possibly the-clamp,we overexpressed short
peptides containing the APIM-consensus in E. coli BL21.
Overexpression of RWLVK and RFSLK strongly inhibited
bacterial growth, while overexpression of a mutated APIM,
RALVK, which is previously shown to have reduced affin-
ity for PCNA both in vivo and in vitro (3,10,26), and the
truncated version of APIM, RWLK, did not inhibit bac-
terial growth (CFU determination in Figure 1D, OD mea-
surements in Supplementary 1A). The expression levels for
the same APIM-versions fused N-terminally to EYFP were
equal, suggesting that the difference in growth-inhibiting
potential was not due to differences in peptide expression
(Supplementary Figure S1B).
APIM-peptides interact with the -clamp
Initial in vitro binding experiments by MST indicated that
cell penetrating versions of the RWLVK and RFSLK-
peptides had higher affinities (KDs < 50 M) for the -
clamp than the corresponding RALVK-peptide (KD > 750
M), and that no binding was detected for the truncated
APIM-peptide RWLK and R11 (Supplementary Figure
S2A). Next, we examined the direct interaction between
the -clamp and octamer peptides containing RWLVK
and RALVK (i.e. without the cell penetrating part of the
peptide) by SPR. Similar to what was indicated by the
initial fluorescence measurements, the peptide containing
RWLVK bound stronger to the -clamp than RALVK
(Figure 2A), which is in accordance with what is previ-
ously seen for the interaction of RWLVK and RALVKwith
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Figure 1. Cell penetrating peptides containing APIM (APIM-peptides) have growth inhibitory activities. (A) MIC determination (g/ml and M) for
the cell penetrating APIM-peptide RWLVK (MW = 3674 Da) in different strains of S.aureus. MICs for ciprofloxacin (MW = 313 Da) for the strains
determined in parallel experiments are given as a reference. The same results were obtained in three biological replicates (n = 3). (B) Inhibition of growth
(OD600) of four different clinical isolates of multidrug-resistant S. epidermidis after the addition of the cell penetrating RWLVK-peptide. Data are given
as % of untreated parallel of the same isolate. (C) MIC determination of S. epidermidis (MRSE), and two E. coli strains (BL21 and MG1655) for different
cell penetrating APIM-peptide variants (connected to R11) or the cell penetrating peptide only (R11). Peptides marked with an asterisk (*) are peptides
connected to R11 with linker ‘GILQ-WRKI’ instead of ‘W-KKKRK-I’. MIC-values are average of ≥3 independent biological experiments. (D) The effect
of expressing different APIM-peptide variants without the cell penetrating peptide in E. coli BL21. The expression was induced with IPTG (1 mM) at ‘0 h’
in exponentially growing cultures. Growth (CFU/ml) 2 and 8 h after induction is displayed relative to its own uninduced culture (%). ‘Control’ culture =
BL21 cells. Data presented represent average data from three technical replicas from ≥3 independent biological experiments (≥2 different bacteria clones
for each peptide variant). P < 0.0001****, P < 0.001***, P < 0.01**, P < 0.05*, two-way ANOVA.
PCNA (26). We further analyzed the binding of the same
octamer peptides to the -clamp using 1D 1H NMR spec-
troscopy (Supplementary 2B). Here, we included a posi-
tive control octamer peptide containing the -clamp bind-
ing peptide from the disordered far C-terminal end of Pol
III, 1153EQVELEFD1160, with a KD of ∼2 M (41) con-
taining a CBM consensus sequence (Supplementary 2B).
From the KDs, we expected the RWLVK-peptide to be in
fast exchange between free and bound state on the NMR
time scale, which would result in a visual line broadening
effect already at a peptide: -clamp ratio of 100:5, whereas
for Pol III -clamp binding peptide, we would expect slower
exchangewith loss of signal from the bound state. To be able
to see this, we analyzed the Pol III -clamp binding peptide
at a ratio of 50:20. Indeed, visual line broadening was seen
for RWLVK already at 100:5 and a similar effect was seen
for the -clamp binding peptide from Pol III at a ratio of
50:20. No chemical shift- or intensity changes were seen for
the addition of the -clamp to the RALVK, showing that
at these concentrations we could not detect any binding of
this peptide to the -clamp by NMR. Thus, the RWLVK,
but not the RALVK peptide bound directly to the -clamp
in these experiments, as did the peptide from Pol III.
To determine where the peptides bound on the -clamp,
mutations in the region previously shown to interact with
CBMs of the polymerases were prepared (mutated residues:
H148K, M362D, V151A, P363D, P242D, V247F, shown in
orange in Figure 2C and D). Mutation of P363 of the -
clamp (P363S) has previously been shown to severely im-
pair interaction with both Pol V (UmuC) and Pol III (
subunit) (16), in addition to impair Pol V dependent muta-
genesis (55). P363 is directly interacting with peptides con-
taining CBM from Pol V (UmuC) (shown in Figure 2C), in
addition to peptides containing the -clamp binding pep-
tide 1153EQVELEFD1160 from Pol III (17). The more dis-
tant residues 148–152 form a loop in the -clamp which is
important for interaction with DNA in addition to inter-
actions with all the TLS polymerases, even though the dif-
ferent TLS polymerases interact with this loop differently
(56,57). All the variants of the -clamp were found to have
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Figure 2. APIM-peptide variant RWLVK interacts with the -clamp. (A) SPR analysis of immobilized WT -clamp and the octamer peptide containing
APIM,MDRWLVKW and mutated APIM,MDRALVKW. (B) SPR analysis of immobilized mutant -clamps (H148K,M362D, V151A, P363D, P242D,
V247F) and theMDRWLVKW-peptide. (C andD) Structural modeling of peptide interactions with the -clamp (C) CBM from Pol V (UmuC), AQLNLF,
(from (17)), and (D) part of the APIM-peptide, MDRWL. Mutated residues, used in (B), are highlighted in orange. Underlined amino acids are part of
APIM or CBM consensus sequences. (E) Structure of PIP-box and APIM in ZRANB3 bound to PCNA (11,58), CBM from Pol V bound to the -clamp
(17) and a homology model of the MDRWL-part of the APIM-peptide based on alignment with the QLNL-part of the Pol V CBM-peptide. Blue and
green circles illustrate the hydrophobic pocket/subsite I and Q-pocket/subsite II, respectively. Residues interacting with these pockets are shown with blue
and green color in the sequence display (inset), respectively. The protein surfaces are colour coded from white to red according to the hydrophobicity index
(66).
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reduced ability to bind RWLVK, with the -clampV247F
being most affected with ∼50% reduced binding (Figure
2B).
The DNA-clamps from all three kingdoms of life share
structural properties, such as the presence of a peptide-
binding groove in the C-terminal region essential for in-
teractions with the clamp binding motifs (reviewed in (1),
and illustrated for the -clamp and PCNA in Figure 2E).
The five–six amino acids of CBM (QL-x1–2-LF) and what
is believed to be its successor, the PIP-box (Q-xx-M/L/I-
xx-FF/Y), share some similarities, while less similarity is
found between CBM and APIM (R/K-F/Y/W-L/I/V/A-
L/I/V/A-R/K). However, despite low similarity between
APIM and PIP-box, it is shown that they have overlap-
ping interaction site on PCNA (11,58). Analysis have shown
that F2, L3 and K5 in the APIM sequence of ZRANB3
(SDITRFLVK, APIM underlined) binds in the hydropho-
bic pocket, also called the ‘socket’, of PCNA, forming a
hydrophobic plug, and that an S- and I- residue four and
two residues upstream of APIM, respectively, bind to the Q-
pocket of PCNA (58). The corresponding amino acids in the
PIP-box inZRANB3 (QHDIRSFF) are FF and I binding in
the socket and Q in the Q-pocket (Figure 2E). The socket in
PCNA corresponds to interaction subsite I on the -clamp,
and the Q-pocket is often referred to as subsite II (41). It is
suggested that the pair of hydrophobic residues at positions
four/five or five/six in CBM (i.e. L4F5 for Pol V) comprise
the core of CBM and that these interact with subsite I on
the -clamp (14). Based on the resemblance in structure be-
tween the -clamp and PCNA, and the known co-structure
of the Pol V (UmuC) CBM, QLNLF and the -clamp (17),
we suggest that WL in the APIM-peptide (MDRWLVK)
bind in subsite I and MD in subsite II (Figure 2D and E).
In this homology model, W4, forms interactions with V247
and/or M362. A peptide docking of this initial model us-
ing the Rosetta FlexPepDock protocol suggests that the W-
residue might interact with subsite I in two different orien-
tations (Supplementary Figure S3A–E). Experimental data
is required to verify this and to delineate how the down-
stream residues within APIM (VK) and residues outside the
APIM-motifs interact with the -clamp. Flanking residues
of both the PIP-box and APIM are shown to have a role for
binding to PCNA (59,60).
APIM-peptides inhibit DNA replication
In order to directly test whether APIM-peptides inhibit the
process of DNA replication we performed flow cytometry
analysis of theDNA content inE. coliMG1655 cells treated
with the cell penetrating RWLVK*-peptide and compared
it to untreated cells and cells treated with the cell penetrat-
ing part only, R11. In this assay, the cells treated with Rif
and Cpx cannot initiate new rounds of replication or di-
vide but can perform run-out of already initiated replica-
tion (see ‘Materials and Methods’ section). DNA replica-
tion was partially inhibited by RWLVK* at 2 and 4 M,
and completely inhibited at 6 M (Figure 3A, illustrated
in 3C). The DNA histograms also indicated that treatment
with RWLVK* initiated DNA degradation, likely as a re-
sult of double-strand breaks upon DNA replication fork
arrest. In contrast, the R11 peptide did not have any effect
on DNA replication under these assay conditions even at
concentrations above MIC (15 M), indicating that the cell
penetrating part of the peptide has no direct effect on DNA
replication (Figure 3B).
APIM-peptides strongly inhibit mutagenesis
Because both replicative and TLS DNA polymerases bind
to the same region on the -clamp via their CBMs, the anti-
mutagenic activities of the APIM-peptides, overexpressed
versus added peptide in E. coli BL21 was next compared.
Overexpression of RWLVK and RFSLK containing pep-
tides, both of which strongly inhibited bacterial growth
(Figure 1D), reduced the spontaneous mutation frequency
by>98% (Table 2). Overexpression of the truncated APIM-
peptide, RWLK, which did not inhibit bacterial growth nor
bind to the -clamp (Figure 1D and Supplementary Fig-
ure S2A), did not affect the mutation frequency (Table 2).
The same patterns were seen by addition of cell penetrat-
ing APIM-peptides; however, overexpression reduced the
mutation frequency much more than addition of the same
APIM-variants (Table 2). The R11 cell penetrating peptide
did not affect the mutation frequency.
The strong reduction in RifR colonies detected when
overexpressing peptides compared to adding peptidesmight
be exaggerated due to strong inhibition of growth. Addi-
tionally, the intracellular levels of the APIM-peptides are
likely much lower when added as a cell penetrating pep-
tide compared to when continuously overexpressed. An-
other contributing factor may be different APIM-flanking
regions in the overexpressed peptides (GILQSTLA) com-
pared to the added cell penetrating RWLVK and RFSLK-
peptides (WKKKRKI) used in these experiments. Flanking
regions could influence import, the stability of the peptides
(both in the media and inside the bacteria), and/or inter-
actions with the -clamp as well as contribute to negative
selection as seen for PCNA ligands (60).
Next, the ability of the cell penetrating APIM-peptides
to reduce UV-induced mutation frequency was examined.
RWLVK, which binds to the -clamp, but not the much
weaker -clamp binder, RALVK, reduced the mutation fre-
quency (Figure 4A). This further supports that theRWLVK
peptide bind to the same site on the -clamp as the bacte-
rial TLS polymerases, and that the affinities of the APIM-
variants for the -clamp correlated with their ability to in-
hibit mutagenesis. In support for the involvement of flank-
ing regions, reduced MIC (Figure 1C) and more efficient
reduction of the mutation frequency; a 53% reduction us-
ing only 1/6 of the molar concentration was found for the
RWLVK-peptide containing GILQ-WRKI (RWLVK*) in-
stead ofWKKK-RKI (i.e. RWLVK) in front of the cell pen-
etrating peptide sequence (Figure 4A). These results sup-
port that the APIM-flanking regions contribute to the an-
tibacterial and anti-mutagenic activities of the peptides.
To examine the anti-mutagenic effects of cell penetrating
APIM-peptides during antibiotic-induced stress in contin-
uously growing cultures, S. epidermidis was grown in sub-
MIC levels of gentamicin with and without the RFSLK-
peptide and the fractions of gentamicin resistant (GenR)
bacteria were determined. Several antibiotics are shown to
induce SOS in S. aureus (61,62), and sub-lethal concentra-
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Figure 3. APIM-peptide variant RWLVK* blocks DNA replication in E. coli MG1655 cells. (A) Flow cytometry histograms showing the DNA content
of cell penetrating RWLVK* treated cells. The top row shows the DNA histograms of cells growing exponentially, whereas the lower row shows the DNA
histograms of cells treated with rifampicin (Rif) and cephalexin (Cpx) to allow for run-out of replication. The peptide concentrations (2–6M) are depicted
in the figure. (B) Flow cytometry histograms showing the DNA content of untreated andR11-peptide treated cells. The top row shows the DNAhistograms
of cells growing exponentially, whereas the lower row shows the DNA histograms of cells treated with Rif and Cpx. The peptide concentrations (2–15 M)
are depicted in the figure. (C) Schematic cartoon illustrating the DNA content in actively replicating cells of exponentially growing cultures (left), the fully
replicated chromosomes in cells treated with Rif and Cpx (mid), and inhibition of replication with for example RWLVK* treatment which lead to no
run-out to produce four and eight chromosomes (right).
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Table 2. APIM-peptide variants reduce spontaneous mutation frequency
in E. coli. Overexpression of RWLVK (n = 5), RFSLK (n = 5), RWLK (n
= 6) and empty vector/control (n = 12) was conducted in E. coli BL21
Mutation frequency (RifR/108 CFU)
Peptide-variants
Overexpressed
peptides Added peptides
no peptide (control) 2.5 ± 0.4 10.5 ± 2.2
RWLVK 0.02 ± 0.01 ** 5.9 ± 2.3 **
RFSLK 0.01 ± 0.003 ** 4.1 ± 1.6 *
RWLK 3.8 ± 1.2 7.7 ± 3.3
R11 na 7.2 ± 3.9
Addition of cell penetrating peptide variants (20M) containingRWLVK
(n = 11), RFSLK (n = 4), RWLK (n = 7), R11 only (n = 5) and no
peptide/control (n = 11) was conducted in E. coli MG1655. Average ±
SEM, n = independent biological experiments. Two tailed, paired t-test, P
< 0.05*, P ≤ 0.005**.
tions of gentamicin is shown to induce SOS in E. coli (63).
The bacterial cultures were treated on day 1 and grown for
three additional days with daily re-inoculation (1:100) in
media containing fresh drugs. The cultures that were grown
with a low dose of only gentamicin quickly (after 2 days) de-
veloped a statistically significant fraction of gentamicin re-
sistance bacteria compared to those grown in cultures with
the combination of gentamicin and the RFSLK-peptide
(Figure 4B). RFSLK-peptide addition alone did not change
the mutation frequency compared to the control. This in-
dicates that APIM-peptides used in combination with gen-
tamicin can inhibit resistance development and supports
that the APIM-peptides inhibits TLS.
APIM-peptides mainly inhibit Pol V-mediated TLS
To investigate the role of the individual TLS polymerases
and the anti-mutagenic activity of the cell penetrating
RWLVK APIM-peptide after induction of SOS by UV-
irradiation, we made single, double and triple TLS poly-
merase deletion mutants in E. coliMG1655. The RWLVK-
peptide significantly reduced the spontaneous mutation fre-
quency inwild type (WT), but not in any of the TLSdeletion
strains (Figure 4C, black *). Interestingly, increased muta-
tion frequency was detected in the Pol II/V strain, sug-
gesting that the RWLVK-peptide has a larger capacity for
inhibiting the binding of Pol III to the -clamp than Pol IV
under these conditions. Inducing SOS with UV-irradiation
increased the mutation frequency in all the Pol V proficient
strains (Figure 4C, red *), in accordance with Pol V being
the main TLS polymerase for bypass of UV-damages (64).
Treatment with the RWLVK-peptide reduced the mutation
frequency in all Pol V containing strains after UV-damage
(Figure 4C, blue *). In the Pol IV/V strain we could not
detect any significant increase in mutation frequency after
UV-irradiation; still, we detected a reduction in the muta-
tion frequency after RWLVK-peptide treatment. This may
indicate an increased affinity of RWLVK for the -clamp
after SOS similarly to what is seen for the APIM-PCNA in-
teraction upon DNA damage and poly-ubiquitination (22).
This could be mediated by modifications on the -clamp
and/or other accessory proteins and could potentially ex-
plain the low in vitro affinity of the peptides for purified -
clamp compared to the high capacity for inhibiting replica-
tion and TLS in vivo. Strains lacking Pol II grew slower and
were also less inhibited by the APIM-peptide than the other
strains, both under untreated conditions and after SOS in-
duction (Supplementary Figure S4), supporting that repli-
cation is targeted by the APIM-peptide. Taken together,
these results suggest that the APIM-peptide can inhibit the
interaction of Pol II and Pol V with the -clamp, and that
this is more pronounced after SOS induction (UV). No re-
duction of mutation frequency was detected in the TLS de-
ficient Pol II/IV/V strain by APIM-peptide addition un-
der any conditions. When examining the mutation spectra
in the rpoB gene we found that the RWLVK-peptide mod-
ulated the pattern of mutations; however, no clear trends in
the mutation spectra from the different strains could be ex-
tracted (data not shown).
In summary, these results suggest that APIM-peptides
compete with the TLS polymerases for binding to the -
clamp. This further suggests that the region harboring sub-
site I and subsite II in the C-terminal part of the -clamp is
capable of interacting with a wide range of peptides diverg-
ing from the rather broadly defined CBM, as well as clamp
binding motifs from eukaryotes. This region in PCNA is
also promiscuous and can bind to a wide range of PIP-box
and APIM-variants (11,60,65).
In vivo proof of concept; APIM-peptides strongly reduce the
growth of MRSA in a skin infection model in mice
At last, as an in vivo proof of concept we tested the efficacy
of the cell penetrating RFSLK APIM-peptide in a murine
skin infection model. Superficial skin wounds on the back
of mice was infected withMRSA and treated topically with
a methyl cellulose gel containing APIM-peptide twice a day
for 3 days.We found that theAPIM-peptide gel significantly
reduced the bacterial load in the infected lesions compared
to controls only treated with the empty gel (Figure 5). High
efficacy was achieved even though this pilot gel formula-
tion was not optimal, being of much lower viscosity than
the positive control (fusidic acid ointment). However, and
more importantly, no toxicity of the APIM-peptide gel was
detected. Although we cannot directly compare the activ-
ity of the APIM-peptide with fusidic acid in this experi-
ment, a significant reduction in bacterial load was detected
at a 10-fold lowermolar concentration of theAPIM-peptide
than fusidic acid, showing great promise for further devel-
opment.
Concluding remarks
Based on the observed similarity in polymerase binding
sites between PCNA and the -clamp, published data and
our results, we find that peptides containing APIM bind
to both PCNA and the -clamp. The APIM-peptides in-
hibit bacterial growth at lower concentrations than needed
for growth inhibition of the most sensitive cancer cells
(10). The direct interaction with the -clamp likely medi-
ates parts of the APIM-peptides’ growth inhibition and all
their anti-mutagenic properties. APIM-peptides have anti-
mutagenic activities at doses below MICs, suggesting that
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Figure 4. APIM-peptides inhibit TLS. (A) Spontaneous and UV induced (2 mJ/cm2) mutation frequency in E. coli MG1655 cells after the addition of
the cell penetrating RWLVK or RALVK-peptides (20 M), n = 8 and n = 7 respectively, or RWLVK*-peptide (3.3 M), n = 7. The bars represent
fraction of rifampicin resistant CFU (RifR/108) of n = independent biological experiments relative to control (%) ± SEM. Control = no peptide added,
represented by the dotted line. Two-tailed, paired t-test against control, P< 0.05*, P< 0.001***. (B) Mutation frequency in a gentamicin sensitive clinical
isolate of Staphylococcus epidermidis after incubation with gentamicin (0.25 g/l) and/or the cell penetrating RFSLK APIM-peptide (3 M) for 4 days.
Control = no treatment. Mutation frequency is shown as average gentamicin resistant CFU (GenR/108) from n ≥ 4 independent biological experiments
± SEM, gray area = mutation frequency ± SEM of the control culture. P < 0.0001****, two-way ANOV A. (C) Spontaneous and UV induced (2
mJ/cm2) mutation frequency in E. coli MG1655 in WT and TLS deletion mutant cells after addition of the cell penetrating RWLVK-peptide (20 M).
Spontaneous mutation frequency from untreated cultures (white bars, control) and after addition of APIM-peptide (white bars with a shaded pattern,
RWLVK). Mutation frequency in UV-irradiated cultures without treatment (gray bars, control + UV) and after addition of APIM-peptide (gray bars with
a shaded pattern, RWLVK + UV). Black* = significant change from untreated culture after RWLVK-peptide addition, Red* = significantly increased
mutation frequency from untreated cultures after UV-irradiation. Blue* = significantly reduced mutation frequency after addition of RWLVK-peptide
to UV-irradiated cultures. Average mutation frequency (RifR/108) ± SEM, n = 8–10, n = independent biological experiments. Two-tailed, paired t-test
relative to WT control, P < 0.05*.
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Figure 5. APIM-peptides significantly reduce growth in a superficial skin infectionmodel inmice.Growth ofMRSA43484 inmouse skin lesions (CFU/skin
lesion) on day 4. Skin lesions were infected on day 0 and treated topically twice per day with the cell penetrating RFSLK-APIM peptide (13 mg/ml, 3.5
mM) or fusidic acid (19 mg/ml, 37 mM) on day 1–3. No treatment = control. The dashed line represents the mean of inoculum (CFU/skin lesion) from
animals sacrificed on day 1, before treatment start. P < 0.001***, P < 0.0001****, ANOVA, multiple comparisons.
the TLS Pol II and Pol V are efficiently inhibited at con-
centrations not completely blocking Pol III mediated repli-
cation. To our knowledge, no other specific inhibitor(s)
of bacterial TLS polymerases/processes has been devel-
oped; thus, the APIM-peptide’s ability to reduce mutage-
nesis might have great potential in the battle against the de-
velopment of antibiotic resistance if used in combination
with other antibiotics. In vivo proof of concept in a murine
skin infection model supports further development of these
peptides.
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